Author: Mitchell Gaydash
Derivation of a Point of Departure from In Vitro Methods for use in Skin Sensitization Risk Assessment Pt 1
February 7, 2023This webinar explores the use of Non-Animal Methodologies to derive a Point of Departure (predicted LLNA EC3) which can be used to evaluate the skin sensitization potency as well as downstream use for risk assessment. Presenters include: Dr. Argel Islas-Robles (Study Director and Toxicologist, IIVS) and Dr. Andreas Natsch (Senior Research Fellow, Givaudan)....
IIVS Leadership Newsletter
February 3, 2023Please join me in congratulating Amanda Ulrey and Kristie Sullivan on their new roles as they work with Hans Rabe, Senior Vice President and Chief Operation Officer, and the rest of the IIVS team to further the IIVS mission of advancing the use and acceptance of non-animal approaches worldwide....
November 2022 Newsletter
November 10, 2022IIVS is pleased to announce the appointment of Amanda Ulrey to our Board of Directors. As a 20-year veteran at IIVS, Mandy is currently Vice President of Business Operations and where she is primarily responsible for instituting quality management systems and regulatory compliance throughout the organization, as well as administering IIVS’ business-to-business certification in Good In Vitro Method Practices (GIVIMP)....
Experimental Toxicology and Ecology of BASF receives certification for Good In Vitro Method Practices
October 19, 2022Ludwigshafen, Germany and Gaithersburg, Maryland, USA – October 19, 2022 – The Institute for In Vitro Sciences (IIVS) certified BASF’s Experimental Toxicology and Ecology for Good In Vitro Method Practices (GIVIMP) based on the guidance document published in 2018 by the Organization of Economic Cooperation and Development (OECD). The GIVIMP document provides principles in quality management which, when implemented, serve to increase the quality and confidence in data generated by in vitro test methods. ...
Good In Vitro Method Practices Certification: A Roadmap for Implementation and Harmonization
October 7, 2022The Organization for Economic Cooperation and Development (OECD) guidance document on Good In Vitro Method Practices (GIVIMP) details a set of quality standards to improve both the quality of and confidence in newly developed, and routinely executed in vitro methods. Currently a practical guide to implement GIVMP standards is missing; leaving organizations to define the best approach for themselves. ...
What’s New at IIVS – Sept. 2022
September 14, 2022Dr. Dan Bagley joins the IIVS Board of Directors; President of IIVS Recognized with Award by PCRM; Award for IIVS Training on Alternative Methods IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series” focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the...
IIVS Toxicologist Presents on Safety Testing in Latin America
September 1, 2022IIVS Toxicologist Dr. Argel Islas-Robles participated last week as speaker on the “In Vitro Science Webinars Series" focusing on the topic of non-Animal Methods for dermal and ocular testing on personal care and cosmetics (presentation in Spanish). This was first in a series of events designed to highlight New Approach Methodologies (NAMs) for human and environmental safety without the use of animal experimentation in Latin America. Watch the full video here: https://www.youtube.com/watch?v=9f9ub6Httls: El Toxicólogo de IIVS, Dr. Argel Islas-Robles, participó la semana...
IIVS is Pleased to Announce the Co-Publication of Three Articles
August 25, 2022IIVS is pleased to announce the co-publication of several respiratory-based articles highlighting: the characterization and recommendations for non-animal techniques used to model mucociliary clearance in human-derived test systems, the dosimetry of tobacco products for in vitro testing and a third article covering the use of New Approach Methodologies to nicotine containing products in a regulatory environment. Key Challenges for In Vitro Testing of Tobacco Products for Regulatory applications: Recommendations for Dosimetry Ciliary Beat Frequency: Proceedings and Recommendations from a Multi-laboratory Ring Trial Using...
May 2022 Newsletter
July 1, 2022The ability to ascertain the maximum limit of a compound that can be applied to the skin without inducing skin sensitization is a critical safety criterion for virtually any risk assessment. Using regression models developed by Givaudan (Kempthal, Switzerland), IIVS is able to perform a computational approach to determine predicted EC3 values (Effective Concentration required to induce a 3-fold upregulation of lymph node cell proliferation) using a combination of OECD approved assays (KeratinoSens, hCLAT, and kDPRA). This value can be used to assess risk for compounds to...
IIVS News and Updates June 2022
July 1, 2022NEW! Good In Vitro Method Practices (GIVMP) Certification IIVS is pleased to announce our new business-to-business GIVIMP Certification Program created to help laboratories: As an OECD guidance document, GIVIMP sets forth internationally recognized quality standards to help ensure that new in vitro methods are ready for implementation, and to foster confidence in the resulting data for use by industry or regulatory bodies....